The Cooper Companies (COO)
(Delayed Data from NSDQ)
$92.69 USD
+0.08 (0.09%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$92.69 USD
+0.08 (0.09%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
Merit Medical (MMSI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 17.91% and 1.26%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
COO vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
COO vs. ALGN: Which Stock Is the Better Value Option?
Here's Why You Should Add Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Align Technology (ALGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 13.82% and 1.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Cooper Companies (COO) Q4 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal fourth-quarter revenues reflect a solid segmental performance.
The Cooper Companies (COO) Q4 Earnings Miss Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of -11% and 1.03%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.
Earnings Preview: The Cooper Companies (COO) Q4 Earnings Expected to Decline
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Motus GI Holdings, Inc. (MOTS) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Motus GI Holdings, Inc. (MOTS) delivered earnings and revenue surprises of 9.63% and 14.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.73% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 25% and 5.81%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Alcon (ALC) Clareon Suite to Get a Boost With Product Launch
by Zacks Equity Research
With the latest launch of Clareon Toric, Alcon's (ALC) Clareon Collection of IOLs is complete in the United States.
The Cooper Companies (COO) Down 10.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
The Cooper Companies (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal third-quarter earnings reflect solid segmental performance.
The Cooper Companies (COO) Lags Q3 Earnings Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of -0.31% and 1.44%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.
Analysts Estimate Patterson Cos. (PDCO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Patterson Cos. (PDCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate The Cooper Companies (COO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
The Cooper Companies (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
Assure Holdings Corp. (IONM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -60.87% and 72.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health (CAH) Lags Q4 Earnings Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of -10.26% and 5.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 14th
by Zacks Equity Research
COO, AMG, and IVZ have been added to the Zacks Rank #5 (Strong Sell) List on July 14, 2022.